Lyra Therapeutics share price logo

Lyra Therapeutics

OTC: LYRA

$0.19

Live

as on

Lyra Therapeutics Stock Performance

as on October 20, 2026 at 6:56 am IST

  • Day's Low

    $0.03
    $0.19
    downward going graph

    84.21%

    Downside

  • 52 Week's Low

    52 Week's High

    $0.00
    $6.73
    downward going graph

    99.79%

    Downside

    3439.47%

    Upside

    downward going graph

Lyra Therapeutics share price movements today

Previous Close
$0.19
Open
$0.19
Volume
42.2K
Market Cap
$337.2K
Day's Low - High
$0.03 - $0.19
52 Week Low - High
$0.00 - $6.73

Lyra Therapeutics Historical Returns

1 Month Return
-5 %
3 Month Return
-63.46 %
1 Year Return
-96.97 %
3 Year Return
-99.89 %
5 Year Return
-99.95 %

Lyra Therapeutics Stock Fundamentals & Key Indicators

Check Lyra Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$337.2K

EPS (TTM)

-18.62

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.01

Industry PE ratio

-4.13

PEG Ratio

0.00

EBITDA

-27.8M

Revenue (TTM)

398.0K

Profit Margin

100.00%

Return On Equity TTM

455.31%

Lyra Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Lyra Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Lyra Therapeutics image
Lyra Therapeutics
Buy$337.2K-99.95%-0.01100.00%0.00%
Alnylam Pharma image
Alnylam Pharma
StrongBuy$30.1B14.44%36.9079.72%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.9B191.61%30.2886.04%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$44.0BNA27.4787.82%0.00%
Regeneron image
Regeneron
Buy$83.1B43.11%19.2484.86%0.46%

Stock Returns calculator for Lyra Therapeutics Stock including INR - Dollar returns

The Lyra Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Lyra Therapeutics investment value today

Current value as on today

₹3,272

Returns

-₹96,728

(-96.73%)

Returns from Lyra Therapeutics Stock

-₹96,975 (-96.97%)

Dollar Impact

₹247 (+0.25%)

Analyst Recommendation on Lyra Therapeutics Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Lyra Therapeutics. Average target price of $16

Lyra Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Lyra Therapeutics.

What analysts predicted

98.81%UPSIDE

Target Price

$16

Current Price

$0.19

Analyzed by

12 Analysts

Target

$16.00

Lyra Therapeutics target price $16, a slight upside of 98.81% compared to current price of $0.19. According to 12 analysts rating.

Indian Investors' Interest in Lyra Therapeutics Stock

Search interest for Lyra Therapeutics Stock has increased by 2150% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:2150% versus previous 30 day period

Lyra Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
-11
0
0
0
0
0
0
0
0
0
Operating Income
-16
-16
-23
-48
-12
-11
-8
-8
-6
-7
EBITDA
-16
-16
-23
-17
-9
-9
-7
-7
-5
-6
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-15
-15
-22
-48
-11
-10
-8
-7
-5
-6
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-15
-15
-22
-48
-11
-10
-8
-7
-5
-6
Net Profit Margin
-2173.53%
41.78%
74.44%
100.00%
100.00%
100.00%
100.00%
-9.29%
-300.00%
4385.71%

Lyra Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
-
-
0
1
1
1
0
Gross Profit
1
-
-12
-29
1
1
1
0
Operating Income
-7
-16
-22
-43
-56
-67
-96
-31
EBITDA
-7
-16
-22
-42
-53
-65
-60
-29
Interest Expense
-
-
-
-
-
-
-
-
Depreciation
0
0
0
1
1
0
0
0
Income Before Tax
-6
-16
-22
-43
-55
-62
-93
-28
Income Tax Expense
-
-
-
-
0
0
0
0
Net Income
-6
-16
-22
-43
-55
-62
-93
-28
Net Profit Margin
100.00%
0.00%
0.00%
-10318.95%
100.00%
100.00%
100.00%
100.00%

Lyra Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-15
-15
-22
-48
-11
-10
-8
-7
-5
-6
Operating Cash Flow
-14
-19
-22
-19
-16
-11
-8
-6
-7
-6
Investing Cash Flow
-14
-2
7
36
8
28
-
0
-
0
Financing Cash Flow
0
18
8
0
0
0
-
4
0
-
Change in Cash
-29
-2
-5
16
-8
16
-8
-1
-7
-6

Lyra Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-6
-16
-22
-43
-55
-62
-93
-28
Operating Cash Flow
-6
-13
-21
-25
-43
-63
-70
-28
Investing Cash Flow
0
0
-1
-3
-65
-12
80
0
Financing Cash Flow
29
0
87
0
96
65
8
4
Change in Cash
22
-14
64
-28
-12
-10
18
-24

Global Institutional Holdings in Lyra Therapeutics

Check out the Institutions with significant holdings in Lyra Therapeutics.

Funds
Holdings
Fidelity Concord Street Trust
0.67%
Victory Portfolios III
0.14%
ProFunds
0.04%

Insights on Lyra Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 6 quarters, -48.13M → -5.98M (in $), with an average increase of 76.2% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 67.9% return, outperforming this stock by 167.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 24.2% return, outperforming this stock by 118.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, LYRA stock has moved down by -66.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 209.0K → 25.0K (in $), with an average decrease of 32.9% per quarter

About Lyra Therapeutics

Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
OrganisationLyra Therapeutics
Headquarters480 Arsenal Way, Watertown, MA, 02472, US
IndustryBiotechnology
CEOCarmichael S. Roberts Jr.

Key Management of Lyra Therapeutics

Name

Title

Dr. Carmichael S. Roberts Jr., M.B.A., Ph.D.

Co-Founder

Ms. Vineeta Belanger Ph.D.

Senior Vice President of Clinical Affairs

Ms. Allison Nance

Senior Vice President of Regulatory Affairs

Dr. Elazer R. Edelman FACC, M.D., Ph.D.

VP of Finance & Risk

FAQs

What is Lyra Therapeutics share price today?

Lyra Therapeutics share price today is $0.19 as on . Lyra Therapeutics share today touched a day high of $0.19 and a low of $0.03.

What is the 52 week high and 52 week low for Lyra Therapeutics share?

Lyra Therapeutics share touched a 52 week high of $6.73 on and a 52 week low of $0.00 on . Lyra Therapeutics stock price today i.e. is trending at $0.19,which is 97.17% down from its 52 week high and 47400.00% up from its 52 week low.

What is Lyra Therapeutics's market capitalisation today?

Lyra Therapeutics market capitalisation is $0.00T as on .

How to invest in Lyra Therapeutics Stock (LYRA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Lyra Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Lyra Therapeutics Stock (LYRA) from India?

Indian investors can start investing in Lyra Therapeutics (LYRA) shares with as little as ₹94.94000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Lyra Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Lyra Therapeutics share’s latest price of $0.19 as on October 20, 2026 at 1:26 am IST, you will get 52.6316 shares of Lyra Therapeutics. Learn more about fractional shares .

What are the returns that Lyra Therapeutics has given to Indian investors in the last 5 years?

Lyra Therapeutics stock has given -99.95% share price returns and 26.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?